These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 1428403

  • 1. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML, Shalaby MR, Werther W, Presta L, Carter P.
    Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
    [Abstract] [Full Text] [Related]

  • 2. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation.
    Zhu Z, Carter P.
    J Immunol; 1995 Aug 15; 155(4):1903-10. PubMed ID: 7636241
    [Abstract] [Full Text] [Related]

  • 3. Engineering Fab' fragments for efficient F(ab)2 formation in Escherichia coli and for improved in vivo stability.
    Rodrigues ML, Snedecor B, Chen C, Wong WL, Garg S, Blank GS, Maneval D, Carter P.
    J Immunol; 1993 Dec 15; 151(12):6954-61. PubMed ID: 7903100
    [Abstract] [Full Text] [Related]

  • 4. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A, Stevenson GT, Glennie MJ.
    J Immunol; 1991 Jul 01; 147(1):60-9. PubMed ID: 1675655
    [Abstract] [Full Text] [Related]

  • 5. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells.
    Zhu Z, Lewis GD, Carter P.
    Int J Cancer; 1995 Jul 28; 62(3):319-24. PubMed ID: 7628874
    [Abstract] [Full Text] [Related]

  • 6. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY.
    J Immunol; 1994 Mar 01; 152(5):2385-92. PubMed ID: 8133049
    [Abstract] [Full Text] [Related]

  • 7. [High level expression of chimeric antibody fragment F(ab')2 directed against CD20 in Escherichia coli].
    Xiong DS, Zheng MJ, Liu YX, Xu YF, Wang JH, Yang CZ.
    Sheng Wu Gong Cheng Xue Bao; 2004 Sep 01; 20(5):673-8. PubMed ID: 15973988
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Formation of a bispecific antibody by the use of leucine zippers.
    Kostelny SA, Cole MS, Tso JY.
    J Immunol; 1992 Mar 01; 148(5):1547-53. PubMed ID: 1531669
    [Abstract] [Full Text] [Related]

  • 14. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
    Hirsch R, Archibald J, Gress RE.
    J Immunol; 1991 Oct 01; 147(7):2088-93. PubMed ID: 1833451
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.
    Woodle ES, Thistlethwaite JR, Jolliffe LK, Zivin RA, Collins A, Adair JR, Bodmer M, Athwal D, Alegre ML, Bluestone JA.
    J Immunol; 1992 May 01; 148(9):2756-63. PubMed ID: 1533410
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro.
    Molema G, Tervaert JW, Kroesen BJ, Helfrich W, Meijer DK, de Leij LF.
    Br J Cancer; 2000 Jan 01; 82(2):472-9. PubMed ID: 10646907
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.